BioSpace News Archive

Business

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results

Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fourth quarter and full year ending December 31, 2023.

March 7, 2024
·
12 min read
Deals

Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

Ventyx Biosciences, Inc. announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share.

March 7, 2024
·
5 min read
BioMidwest

AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024.

March 7, 2024
·
1 min read
BioMidwest

Lilly’s Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care

Eli Lilly and Company launched the next phase of its Get Better corporate branding campaign with a new focus on obesity.

March 7, 2024
·
3 min read
EurekaBio Completes $40 Million Series B+ Financing to Advance EuLV™ Lentiviral Vector Production System

Shenzhen Eureka Biotechnology Co., Limited (EurekaBio), a leading upstream supplier in the cell and gene therapy field, announced the completion of its Series B+ financing, exceeding $40 million.

March 7, 2024
·
3 min read
Biotech Bay

Synthekine Announces Presentation of Initial Results from Phase 1a/1b Clinical Trial of STK-012 at AACR 2024 Annual Meeting

Synthekine Inc today announced that data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, from April 5-10, 2024.

March 7, 2024
·
2 min read
Biotech Bay

Alto Neuroscience to Participate in Upcoming Investor Conferences - March 7, 2024

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences.

March 7, 2024
·
1 min read
Drug Development

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

A pioneering Phase 1 CAR T cell therapy trial for the treatment of glioblastoma at City of Hope, one of the largest cancer treatment and research organizations in the United States, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

March 7, 2024
·
8 min read
Business

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

KalVista Pharmaceuticals, Inc. announced that Benjamin L. Palleiko, the Company’s current President, CBO and CFO, has been appointed as Chief Executive Officer and a director of the Company, effective immediately.

March 7, 2024
·
4 min read
Business

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today reported financial results for the full year ended December 31, 2023, and recent corporate updates.

March 7, 2024
·
14 min read